TrialClinical rheumatology2007

No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis.

Marco Semmler et al.PubMed ↗Publisher ↗

No numbers read from the abstract.